Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021

Oxidative stress and inflammation have been recognized as important contributors to the risk of chronic non-communicable diseases. Polyunsaturated fatty acids (PUFAs) may regulate the antioxidant signaling pathway and modulate inflammatory processes. They also influence hepatic lipid metabolism and...

Full description

Bibliographic Details
Main Authors: Ivana Djuricic, Philip C. Calder
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/13/7/2421
id doaj-5a4777ae42c740a6b71acc86e54e946d
record_format Article
spelling doaj-5a4777ae42c740a6b71acc86e54e946d2021-07-23T13:59:03ZengMDPI AGNutrients2072-66432021-07-01132421242110.3390/nu13072421Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021Ivana Djuricic0Philip C. Calder1Department of Bromatology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, SerbiaSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UKOxidative stress and inflammation have been recognized as important contributors to the risk of chronic non-communicable diseases. Polyunsaturated fatty acids (PUFAs) may regulate the antioxidant signaling pathway and modulate inflammatory processes. They also influence hepatic lipid metabolism and physiological responses of other organs, including the heart. Longitudinal prospective cohort studies demonstrate that there is an association between moderate intake of the omega-6 PUFA linoleic acid and lower risk of cardiovascular diseases (CVDs), most likely as a result of lower blood cholesterol concentration. Current evidence suggests that increasing intake of arachidonic acid (up to 1500 mg/day) has no adverse effect on platelet aggregation and blood clotting, immune function and markers of inflammation, but may benefit muscle and cognitive performance. Many studies show that higher intakes of omega-3 PUFAs, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a lower incidence of chronic diseases characterized by elevated inflammation, including CVDs. This is because of the multiple molecular and cellular actions of EPA and DHA. Intervention trials using EPA + DHA indicate benefit on CVD mortality and a significant inverse linear dose–response relationship has been found between EPA + DHA intake and CVD outcomes. In addition to their antioxidant and anti-inflammatory roles, omega-3 fatty acids are considered to regulate platelet homeostasis and lower risk of thrombosis, which together indicate their potential use in COVID-19 therapy.https://www.mdpi.com/2072-6643/13/7/2421omega-6 fatty acidsomega-3 fatty acidsinflammationoxidative stressCOVID-19
collection DOAJ
language English
format Article
sources DOAJ
author Ivana Djuricic
Philip C. Calder
spellingShingle Ivana Djuricic
Philip C. Calder
Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021
Nutrients
omega-6 fatty acids
omega-3 fatty acids
inflammation
oxidative stress
COVID-19
author_facet Ivana Djuricic
Philip C. Calder
author_sort Ivana Djuricic
title Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021
title_short Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021
title_full Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021
title_fullStr Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021
title_full_unstemmed Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021
title_sort beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021
publisher MDPI AG
series Nutrients
issn 2072-6643
publishDate 2021-07-01
description Oxidative stress and inflammation have been recognized as important contributors to the risk of chronic non-communicable diseases. Polyunsaturated fatty acids (PUFAs) may regulate the antioxidant signaling pathway and modulate inflammatory processes. They also influence hepatic lipid metabolism and physiological responses of other organs, including the heart. Longitudinal prospective cohort studies demonstrate that there is an association between moderate intake of the omega-6 PUFA linoleic acid and lower risk of cardiovascular diseases (CVDs), most likely as a result of lower blood cholesterol concentration. Current evidence suggests that increasing intake of arachidonic acid (up to 1500 mg/day) has no adverse effect on platelet aggregation and blood clotting, immune function and markers of inflammation, but may benefit muscle and cognitive performance. Many studies show that higher intakes of omega-3 PUFAs, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a lower incidence of chronic diseases characterized by elevated inflammation, including CVDs. This is because of the multiple molecular and cellular actions of EPA and DHA. Intervention trials using EPA + DHA indicate benefit on CVD mortality and a significant inverse linear dose–response relationship has been found between EPA + DHA intake and CVD outcomes. In addition to their antioxidant and anti-inflammatory roles, omega-3 fatty acids are considered to regulate platelet homeostasis and lower risk of thrombosis, which together indicate their potential use in COVID-19 therapy.
topic omega-6 fatty acids
omega-3 fatty acids
inflammation
oxidative stress
COVID-19
url https://www.mdpi.com/2072-6643/13/7/2421
work_keys_str_mv AT ivanadjuricic beneficialoutcomesofomega6andomega3polyunsaturatedfattyacidsonhumanhealthanupdatefor2021
AT philipccalder beneficialoutcomesofomega6andomega3polyunsaturatedfattyacidsonhumanhealthanupdatefor2021
_version_ 1721286553458704384